Copied
 
 
Formål
Formål
Selskabets formål er at drive virksomhed med udvikling og salg af produkter og serviceydelser til brug indenfor drug discovery og anden i forbindelse dermed stående virksomhed.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 28.12.2012 (4146 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 09.07.2001 (8336 dage).
Ingen historik.
Branche
Branche
Konsulentbistand vedrørende informationsteknologi (620200).
Sidst opdateret den 15.06.2009 og angivet som gældende fra 02.01.2008 (5968 dage).
HistorikStartStop
Konsulentbistand vedrørende informationsteknologi (620200)02.01.2008
Virksomhedsrådgivning og anden rådgivning om driftsledelse (702200)01.01.200801.01.2008
Anden virksomhedsrådgivning (741490)09.07.200131.12.2007
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 28.02.2005 (7006 dage).
Ingen historik.
Revisor
Revisor
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
Sidst opdateret den 07.01.2020 og angivet som gældende fra 23.12.2019 (1595 dage).
Form
Virksomhedsform
60.
Sidst opdateret den 28.02.2005 og angivet som gældende fra 24.01.2005 (7041 dage).
HistorikStartStop
6024.01.2005
8009.07.200123.01.2005
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Telefonnummer
88202088.
Sidst opdateret den 17.11.2008 og angivet som gældende fra 13.11.2008 (5652 dage).
Ingen historik.
Navne
Tegningsregel
Tegningsregel
Selskabet tegnes af to bestyrelsesmedlemmer eller af et bestyrelsesmedlem og en direktør i forening.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 28.12.2012 (4146 dage).
Fortolkning (2 tegningsmuligheder)
2 bestyrelsesmedlemmer
1 bestyrelsesmedlem + 1 direktør
Ingen historik.
Ansatte
05.05.2024
Kapital
05.05.2024
Fra årsrapport
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:Deloitte StatsautoriseretRevisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorized Public Accountant
Virksomhedens regnskabsklasse:Reporting class C, medium-size enterprise
Grundlag for konklusion (revision):Basis for opinion We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor’s responsibilities for the audit of the consolidated financial statements and the Parent financial statements” section of this auditor’s report. We are independent of the Group in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the addi-tional ethical requirements applicable in Denmark, and we have fulfilled our other ethical respon-sibilities in accordance with these requirements and the IESBA code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):Opinion We have audited the consolidated financial statements and the parent financial statements of stthVisiopharm A/S for the financial year October 1, 2022 – September 30, 2023, which comprise the income statement, statement of comprehensive income, balance sheet, statement of changes in equity, cash flow statement and notes, including a summary of significant accounting policies, for the Group as well as the Parent. The consolidated financial statements are prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act, and the parent financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the consolidated financial statements give a true and fair view of the Group’s thfinancial position at September 30, 2023, and of the results of its operations and cash flows stthfor the financial year October 1, 2022 – September 30, 2023 in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act. Furthermore, in our opinion, the parent financial statements give a true and fair view of the Parent’s financial position at 30. 09. 2023, and of the results of its operations for the financial year 01. 10. 2022 – 30. 09. 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management's responsibilities for the consolidated financial statements and the parent financial statements Management is responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act, as well as the preparation of parent financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of consolidated financial statements and parent financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated financial statements and the Parent financial statements, Man-agement is responsible for assessing the Group’s and the Parent’s ability to continue as a go-ing concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements unless Management either intends to liquidate the Group or the Entity or to cease operations, or has no realistic alternative but to do so.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
05.05.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
05.05.2024
Ingen nuværende registrering.
Ingen historik.